ReNerve secures positive FDA feedback on NervAlign Nerve Guide Matrix pathway
ReNerve Limited (ASX: RNV) held a positive FDA pre-submission meeting with the US Food and Drug Administration (FDA) on 30 September 2026 for its NervAlign® Nerve Guide Matrix (NGM) program. The meeting was supported in writing.
According to the company’s announcement of 14 October 2026, the FDA confirmed ReNerve’s submission strategy and gave the company a clear path forward for FDA submission ahead of marketing approval clearance. For investors, regulatory clarity before a formal submission may reduce uncertainty on the road to the US market.
When big ASX news breaks, our subscribers know first
What the FDA confirmed
Key feedback from the pre-submission meeting
The company said the discussions were positive and also produced important feedback from the regulator. Three points were highlighted:
- The FDA agreed that the model ReNerve has chosen for its preclinical evaluation is appropriate.
- The FDA provided additional guidance on the control groups it expects.
- The FDA set out clear expectations for the biochemical and biophysical data needed to support clearance.
Agreement on the preclinical model may help protect work already under way. The announcement does not state that the FDA has approved or cleared NGM.
CEO commentary
Dr Julian Chick, CEO of ReNerve
“This is an important step forward for our NervAlign Nerve Guide Matrix program, providing greater clarity on the FDA’s expectations as we progress towards a regulatory submission.”
Dr Chick also said the feedback is “particularly encouraging given the positive results we have from our ongoing preclinical study.” The announcement does not disclose figures from that study.
Understanding the pre-submission pathway
A pre-submission meeting lets a medical device company discuss its regulatory plan with the FDA and seek feedback before making a formal submission. Aligning early on testing and control groups (the comparison groups used to judge a device’s effect) can help limit the risk of rework later.
NGM is described by the company as a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting, according to the company.
The company also cites a global nerve repair market valued at US$1.6 billion in 2024 and projected to reach $6.2 billion by 2031, per the Global Nerve Repair Biomaterials Market Research Report (2020 to 2031).
| FDA feedback area | What the FDA said |
|---|---|
| Preclinical evaluation model | Agreed the model ReNerve has chosen is appropriate |
| Control groups | Provided additional guidance on the control groups it expects |
| Biochemical and biophysical data | Set out clear expectations for the data needed to support clearance |
Next steps and the broader ReNerve story
What happens next
The company outlined the following next steps:
- ReNerve is reviewing the feedback in detail.
- The feedback will be used to finalise its testing plan and the data package for NGM.
- Production continues with its contract manufacturing organisation (CMO).
- The company will update the market on progress, including the timing of planned submission.
The timing of the planned submission has not been disclosed.
Commercial foundation
ReNerve’s FDA-cleared NervAlign® Nerve Cuff is its on-market nerve repair product. In a recently announced clinical study, post-surgical pain scores fell from 7.1 to 0.4 with the device, compared with 7.1 to 3.3 without it, according to the company.
The company reported 53% revenue growth in FY25, reaching $271k in sales. NGM sits in a development pipeline alongside the NervAlign® Nerve Conduit Range and the NervAlign® Bionic Nerve.
Sales momentum has since accelerated, with NervAlign revenue growth reaching 79% quarter-on-quarter in Q3 FY26 and the company recording its first $100,000 sales month in March 2026.
A clearer regulatory path for NGM adds to a pipeline built around an already FDA-cleared, revenue-generating product, though submission timing and any eventual clearance remain undisclosed.
Investors tracking the commercial side of the story can read our detailed coverage of ReNerve’s Asia-Pacific expansion, which covers the first surgeries in Hong Kong and Malaysia and record FY26 sales of $510,357.
Get Healthcare News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving news breaks, and stay ahead of the crowd.